Pharmacodynamics Of Linezolid-Plus-Fosfomycin Against Vancomycin-Susceptible And -Resistant Enterococci In Vitro And In Vivo Of A Galleria mellonella Larval Infection Model

References

• Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2015;34(01):1–14. doi:10.1086/668770
   Web of Science ®Google Scholar
• Hollenbeck BL, Rice LB. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence. 2014;3(5):421–569. doi:10.4161/viru.21282
   Web of Science ®Google Scholar
• Frieden TR, Munsiff SS, Williams G, et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet. 1993;342(8863):76–79. doi:10.1016/0140-6736(93)91285-t8100912
   PubMed Web of Science ®Google Scholar
• Munita JM, Bayer AS, Arias CA. Evolving resistance among gram-positive pathogens. Clin Infect Dis. 2015;61(suppl 2):S48–S57. doi:10.1093/cid/civ52326316558
   PubMed Web of Science ®Google Scholar
• Diazgranados CA, Zimmer SM, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis. 2005;41(3):327–333. doi:10.1086/43090916007529
   PubMed Web of Science ®Google Scholar
• Zasowski EJ, Claeys KC, Lagnf AM, Davis SL, Rybak MJ. Time is of the essence: the impact of delayed antibiotic therapy on patient outcomes in hospital-onset enterococcal bloodstream infections. Clin Infect Dis. 2016;62(10):1242–1250. doi:10.1093/cid/ciw11026945013
   PubMed Web of Science ®Google Scholar
• Mercuro NJ, Davis SL, Zervos MJ, Herc ES. Combatting resistant enterococcal infections: a pharmacotherapy review. Expert Opin Pharmacother. 2018;19(9):979–992. doi:10.1080/14656566.2018.147939729877755
   PubMed Web of Science ®Google Scholar
• Reyes K, Bardossy AC, Zervos M. Vancomycin-resistant enterococci. Infect Dis Clin North Am. 2016;30(4):953–965. doi:10.1016/j.idc.2016.07.00927660091
   PubMed Web of Science ®Google Scholar
• Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36(2):159–168. doi:10.1086/34574412522747
   PubMed Web of Science ®Google Scholar
• Frippiat F, Derue G. Causal relationship between neuropathy and prolonged linezolid use. Clin Infect Dis. 2004;39(3):439. doi:10.1086/422147
   Web of Science ®Google Scholar
• Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother. 2003;37(4):517. doi:10.1345/aph.1C36112659607
   PubMed Web of Science ®Google Scholar
• Smith TT, Tamma PD, Do TB, et al. Prolonged linezolid use is associated with the development of linezolid-resistant Enterococcus faecium. Diagn Microbiol Infect Dis. 2018;91(2):161–163. doi:10.1016/j.diagmicrobio.2018.01.02729496381
   PubMed Web of Science ®Google Scholar
• Sastry S, Doi Y. Fosfomycin: resurgence of an old companion. J Infect Chemother. 2016;22(5):273–280. doi:10.1016/j.jiac.2016.01.01026923259
   PubMed Web of Science ®Google Scholar
• Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother. 2012;56(11):5744–5748. doi:10.1128/AAC.00402-1222926565
   PubMed Web of Science ®Google Scholar
• Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321–347. doi:10.1128/CMR.00068-1526960938
   PubMed Web of Science ®Google Scholar
• Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):e732–e739. doi:10.1016/j.ijid.2011.07.00721945848
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing:  29th ed. CLSI Supplement  M100. Wayne(PA): CLSI; 2019.
   Google Scholar
• Homan WL, Tribe D, Poznanski S, et al. Multilocus sequence typing scheme for Enterococcus faecium. J Clin Microbiol. 2002;40(6):1963–1971. doi:10.1128/jcm.40.6.1963-1971.200212037049
   PubMed Web of Science ®Google Scholar
• Milne KE, Gould IM. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J Antimicrob Chemother. 2010;65(1):82–90. doi:10.1093/jac/dkp38419861334
   PubMed Web of Science ®Google Scholar
• Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemother. 2008;61(2):365–370. doi:10.1093/jac/dkm45718079128
   PubMed Web of Science ®Google Scholar
• Luther MK, Arvanitis M, Mylonakis E, LaPlante KL. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae. Antimicrob Agents Chemother. 2014;58(8):4612–4620. doi:10.1128/AAC.02790-1324867993
   PubMed Web of Science ®Google Scholar
• Simner PJ, Adam H, Baxter M, et al. Epidemiology of vancomycin-resistant enterococci in Canadian hospitals (CANWARD study, 2007 to 2013). Antimicrob Agents Chemother. 2015;59(7):4315–4317. doi:10.1128/AAC.00384-1525896693
   PubMed Web of Science ®Google Scholar
• Scheetz MH, Knechtel SA, Malczynski M, Postelnick MJ, Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother. 2008;52(6):2256–2259. doi:10.1128/AAC.00070-0818391028
   PubMed Web of Science ®Google Scholar
• Yim J, Smith JR, Rybak MJ. Role of combination antimicrobial therapy for vancomycin-resistant enterococcus faecium infections: review of the current evidence. Pharmacotherapy. 2017;37(5):579–592. doi:10.1002/phar.192228273381
   PubMed Web of Science ®Google Scholar
• Tang HJ, Chen CC, Zhang CC, et al. In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates. Diagn Microbiol Infect Dis. 2013;77(3):254–257. doi:10.1016/j.diagmicrobio.2013.07.01224029433
   PubMed Web of Science ®Google Scholar
• Chai D, Liu X, Wang R, Bai Y, Cai Y. Efficacy of linezolid and fosfomycin in catheter-related biofilm infection caused by methicillin-resistant Staphylococcus aureus. Biomed Res Int. 2016;2016:1–7. doi:10.1155/2016/6413982
   Web of Science ®Google Scholar
• Oliva A, Furustrand Tafin U, Maiolo EM, Jeddari S, Betrisey B, Trampuz A. Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model. Antimicrob Agents Chemother. 2014;58(3):1284–1293. doi:10.1128/AAC.02583-1224145537
   PubMed Web of Science ®Google Scholar
• Britt NS, Potter EM, Patel N, Steed ME. Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant Enterococcal bloodstream infection: a national cohort study of veterans affairs patients. Clin Infect Dis. 2015;61(6):civ444. doi:10.1093/cid/civ444
   Web of Science ®Google Scholar
• Hansjürg E, Javier G-F, Christine F, et al. Heteroresistance to fosfomycin is predominant in Streptococcus pneumoniae and depends on the murA1 gene. Antimicrob Agents Chemother. 2013;57(6):2801–2808. doi:10.1128/AAC.00223-1323571543
   PubMed Web of Science ®Google Scholar
• Guo Y, Tomich AD, McElheny CL, et al. High-level fosfomycin resistance in vancomycin-resistant Enterococcus faecium. Emerg Infect Dis. 2017;23(11):1902–1904. doi:10.3201/eid2311.17113029048285
   PubMed Web of Science ®Google Scholar
• Tang HJ, Chen CC, Cheng KC, et al. In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms. J Antimicrob Chemother. 2012;67(4):944–950. doi:10.1093/jac/dkr53522258931
   PubMed Web of Science ®Google Scholar
• Descourouez JL, Jorgenson MR, Wergin JE, Rose WE. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents. Antimicrob Agents Chemother. 2013;57(3):1518–1520. doi:10.1128/AAC.02099-1223263002
   PubMed Web of Science ®Google Scholar
• Colomer-Winter C, Flores-Mireles AL, Baker SP, et al. Manganese acquisition is essential for virulence of Enterococcus faecalis. PLoS Pathog. 2018;14(9):e1007102. doi:10.1371/journal.ppat.100710230235334
   PubMed Web of Science ®Google Scholar
• Cook SM, Mcarthur JD. Developing Galleria mellonella as a model host for human pathogens. Virulence. 2013;4(5):350–353. doi:10.4161/viru.2524023799664
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Loh JM, Proft T. Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing. Virulence. 2016;7(3):214–229. doi:10.1080/21505594.2015.113528926730990
   PubMed Web of Science ®Google Scholar
• Skinner K, Sandoe JAT, Rajendran R, Ramage G, Lang S. Efficacy of rifampicin combination therapy for the treatment of enterococcal infections assessed in vivo using a Galleria mellonella infection model. Int J Antimicrob Agents. 2017;49(4):507–511. doi:10.1016/j.ijantimicag.2016.12.00628235571
   PubMed Web of Science ®Google Scholar
• Glavis-Bloom J, Muhammed M, Mylonakis E. Of model hosts and man: using Caenorhabditis elegans, Drosophila melanogaster and Galleria mellonella as model hosts for infectious disease research. Adv Exp Med Biol. 2012;710:11–17. doi:10.1007/978-1-4419-5638-5_222127881
   PubMed Web of Science ®Google Scholar
• Wojda I. Immunity of the greater wax moth Galleria mellonella. Insect Sci. 2017;24(3):342–357. doi:10.1111/1744-7917.1232526847724
   PubMed Web of Science ®Google Scholar
• Sauermann R, Marsik C, Steiner I, et al. Immunomodulatory effects of fosfomycin in experimental human endotoxemia. Antimicrob Agents Chemother. 2007;51(5):1879–1881. doi:10.1128/AAC.00914-0617353246
   PubMed Web of Science ®Google Scholar